JP2023512174A5 - - Google Patents

Info

Publication number
JP2023512174A5
JP2023512174A5 JP2022542951A JP2022542951A JP2023512174A5 JP 2023512174 A5 JP2023512174 A5 JP 2023512174A5 JP 2022542951 A JP2022542951 A JP 2022542951A JP 2022542951 A JP2022542951 A JP 2022542951A JP 2023512174 A5 JP2023512174 A5 JP 2023512174A5
Authority
JP
Japan
Prior art keywords
compound
salt
cancer
hydrogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542951A
Other languages
English (en)
Japanese (ja)
Other versions
JP7626773B2 (ja
JP2023512174A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/052261 external-priority patent/WO2021156178A1/en
Publication of JP2023512174A publication Critical patent/JP2023512174A/ja
Publication of JP2023512174A5 publication Critical patent/JP2023512174A5/ja
Application granted granted Critical
Publication of JP7626773B2 publication Critical patent/JP7626773B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542951A 2020-02-03 2021-02-01 HER2阻害薬としての[1,3]ジアジノ[5,4-d]ピリミジン Active JP7626773B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20155157.9 2020-02-03
EP20155157 2020-02-03
PCT/EP2021/052261 WO2021156178A1 (en) 2020-02-03 2021-02-01 [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors

Publications (3)

Publication Number Publication Date
JP2023512174A JP2023512174A (ja) 2023-03-24
JP2023512174A5 true JP2023512174A5 (cg-RX-API-DMAC7.html) 2024-02-08
JP7626773B2 JP7626773B2 (ja) 2025-02-04

Family

ID=69467424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542951A Active JP7626773B2 (ja) 2020-02-03 2021-02-01 HER2阻害薬としての[1,3]ジアジノ[5,4-d]ピリミジン

Country Status (5)

Country Link
US (1) US20230126204A1 (cg-RX-API-DMAC7.html)
EP (1) EP4100409B1 (cg-RX-API-DMAC7.html)
JP (1) JP7626773B2 (cg-RX-API-DMAC7.html)
CN (1) CN115052878B (cg-RX-API-DMAC7.html)
WO (1) WO2021156178A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
TW202214641A (zh) * 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Her2突變抑制劑
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
EP4359082A1 (en) 2021-06-26 2024-05-01 Array BioPharma Inc. Her2 mutation inhibitors
WO2023081637A1 (en) 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
US20250206760A1 (en) 2022-03-28 2025-06-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
WO2023195773A1 (ko) * 2022-04-05 2023-10-12 보로노이 주식회사 헤테로아릴 유도체 및 이의 용도
CN117384162A (zh) * 2022-05-17 2024-01-12 浙江文达医药科技有限公司 选择性her2抑制剂
CA3263309A1 (en) 2022-08-22 2024-02-29 Iambic Therapeutics, Inc. HER2 COMPOUNDS AND MODULATION METHODS
AU2023410324A1 (en) 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
AU2024255740A1 (en) * 2023-04-11 2025-10-23 Cogent Biosciences, Inc. Erbb2 inhibitors
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121568696A (zh) 2023-07-28 2026-02-24 勃林格殷格翰国际有限公司 制备her2抑制剂的方法
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
CN122270275A (zh) 2023-08-07 2026-06-23 科景特生物科学公司 用于fgfr抑制的化合物
CN119320383A (zh) * 2023-09-05 2025-01-17 北京鞍石生物科技股份有限公司 含氮杂芳基化合物及其制备方法和应用
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
IL161908A0 (en) 2001-12-12 2005-11-20 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
WO2005044302A1 (en) 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
DE602006021645D1 (de) * 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
LT3077395T (lt) * 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CA2949793C (en) 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
US20210323976A1 (en) 2015-05-13 2021-10-21 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN115057861A (zh) * 2016-03-01 2022-09-16 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
AU2018325442B2 (en) 2017-08-31 2023-04-13 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and/or HER2 and methods of use
CN109422755B (zh) * 2017-09-01 2023-07-04 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
US11608343B2 (en) * 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
EP4637771A1 (en) * 2022-12-22 2025-10-29 Boehringer Ingelheim International GmbH Solid dispersion of a her2 inhibitor
AU2023410324A1 (en) * 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor

Similar Documents

Publication Publication Date Title
JP2023512175A5 (cg-RX-API-DMAC7.html)
JP2986546B2 (ja) スマトリプタンを含有する組成物
ES2935800T3 (es) Forma de dosificación oral de ketamina
CN1248690C (zh) 一种治疗心血管疾病含盐酸雷诺嗪的口服制剂
JP2021536453A5 (cg-RX-API-DMAC7.html)
CN107530348B (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
US11065240B2 (en) Drug combinations to treat multiple myeloma
JP2006523216A5 (cg-RX-API-DMAC7.html)
JP2008521928A5 (cg-RX-API-DMAC7.html)
CN108367005A (zh) 包含酪氨酸蛋白激酶抑制剂的剂型组合物
JP2008540672A (ja) 病状に起因する性的機能不全の治療方法
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
CN101633662A (zh) 普拉格雷的药用酸加成盐及其制备方法和药物应用
WO2016173214A1 (zh) Hsp90抑制肽偶联物及其在肿瘤治疗中的应用
CN101412690A (zh) 西洛多辛的药用酸加成盐及其制备方法和药物应用
JP4852605B2 (ja) 放射線治療増強剤
CN104244952A (zh) 组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途
JP2024525206A (ja) 上皮成長因子受容体阻害剤の医薬組成物
JP2013536243A5 (cg-RX-API-DMAC7.html)
JP2023531930A5 (cg-RX-API-DMAC7.html)
JP2023528896A5 (cg-RX-API-DMAC7.html)
EP2425830A1 (en) Synergistic drug combination for the treatment of cancer
KR20080071193A (ko) 위장 장애의 치료 방법 및 치료 조성물
KR20130078147A (ko) 일정한 입도를 갖는 4,5―디아릴―3(2h)―퓨라논 유도체를 포함하는 약학 조성물
JP2010535212A (ja) 改良されたカンデサルタンの製剤